MCID: HLC007
MIFTS: 59

Helicobacter Pylori Infection

Categories: Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 56 71
Helicobacter Pylori Infection, Susceptibility to 56 29 6 39
H. Pylori Infection, Susceptibility to 56 13
Helicobacter Pylori Infections 42
H. Pylori Infection 56

Characteristics:

OMIM:

56
Inheritance:
not determined


Classifications:



External Ids:

OMIM 56 600263
MedGen 41 C1838332
UMLS 71 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus : 42 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including fever, pruritus and nausea and vomiting. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Acetylcysteine and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver, and related phenotypes are helicobacter pylori infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 56 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 622)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 33.1 S100A8 IL1B GAST CYP2C19 CXCL8
2 atrophic gastritis 31.9 S100A8 MUC6 IL1B GAST CXCL8
3 gastric ulcer 31.8 S100A8 IL1B GAST CYP2C19 CXCL8
4 duodenal ulcer 31.7 S100A8 IL1B GAST CYP2C19 CXCL8 CXCL1
5 microinvasive gastric cancer 31.6 S100A8 MUC6 GAST
6 chlamydia 31.4 NOD1 IL1B CXCL8
7 autoimmune gastritis 31.3 IL1B GAST EGFR
8 chlamydia pneumonia 31.3 S100A8 IL1B CXCL8
9 peptic esophagitis 31.3 S100A8 IL1B GAST CYP2C19 CXCL8
10 gastroduodenitis 31.2 S100A8 GAST
11 gastroesophageal reflux 31.2 S100A8 IL1B GAST EGFR CYP2C19 CXCL8
12 duodenum disease 31.1 S100A8 MUC6 GAST
13 peptic ulcer perforation 31.1 S100A8 GAST
14 exanthem 31.1 IL1B EGFR CXCL8
15 crohn's disease 31.0 S100A8 NOD1 IL1B CXCL8
16 proteasome-associated autoinflammatory syndrome 1 31.0 IL1B CXCL8 CCL5
17 gastritis 31.0 S100A8 NOD1 MUC6 IL1B GAST CYP2C19
18 diarrhea 31.0 IL1B GAST EGFR CXCL8 CXCL1
19 esophagitis 30.8 IL1B GAST EGFR CYP2C19 CXCL8 CCL5
20 prostatitis 30.7 IL1B CXCL8 CASP3
21 cholecystitis 30.7 S100A8 MUC6 EGFR
22 mycobacterium fortuitum 30.7 IFNGR1 CXCL8
23 idiopathic neutropenia 30.4 IL1B CCL5 CASP3
24 shigellosis 30.4 NOD1 NFKBIA IL1B CXCL8
25 appendicitis 30.4 S100A8 IL1B CXCL8
26 tonsillitis 30.4 IL1B CXCL8 CXCL1 CASP3
27 stomach disease 30.3 S100A8 PTPN11 MUC6 IL1B GAST CXCL8
28 gastric cancer 30.2 S100A8 PTPN11 PAK1 MUC6 MET JUN
29 gastroesophageal junction adenocarcinoma 30.2 PAK1 IL1B EGFR
30 gastric adenocarcinoma 30.2 S100A8 MET JUN IL1B GAST EGFR
31 salmonellosis 30.1 JUN IL1B IFNGR1
32 neuritis 30.0 IL1B CXCL8 CCL5
33 gingivitis 30.0 IL1B CXCL8 CCL5
34 monocytic leukemia 30.0 JUN IL1B CXCL8 CASP3
35 pertussis 29.7 JUN IL1B CXCL8 CCL5
36 eye disease 29.2 JUN IL1B CXCL8 CCL5 CASP3
37 cytomegalovirus infection 29.2 NFKB1 IL1B CXCL8 CHUK CCL5 CASP3
38 cystic fibrosis 29.2 S100A8 MUC6 JUN IL1B CXCL8
39 lung disease 29.1 S100A8 MET IL1B IFNGR1 EGFR CXCL8
40 arthritis 29.0 JUN IL1B CXCL8 CXCL1 CCL5
41 t-cell lymphoblastic leukemia/lymphoma 29.0 NFKBIA NFKB1 JUN CHUK CASP3
42 leukemia, acute myeloid 28.8 PTPN11 JUN IL1B EGFR CXCL8 CASP3
43 squamous cell carcinoma, head and neck 28.7 NFKBIA MET JUN EGFR CXCL8 CASP3
44 asthma 28.7 NOD1 NFKBIA JUN IL1B CXCL8 CXCL1
45 rheumatoid arthritis 28.6 NFKBIA JUN IL1B CXCL8 CXCL1 CCL5
46 pancreatic adenocarcinoma 28.5 MUC6 MET JUN IL1B GAST EGFR
47 pancreatic cancer 28.3 NFKBIA NFKB1 MUC6 MET JUN GAST
48 inflammatory bowel disease 28.3 S100A8 NOD1 NFKBIA NFKB1 JUN IL1B
49 hepatocellular carcinoma 27.3 PTPN11 NFKBIA NFKB1 MET JUN IL1B
50 gastric cancer, hereditary diffuse 11.9

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

31
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 31 HP:0005202

Symptoms via clinical synopsis from OMIM:

56
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM:

600263

UMLS symptoms related to Helicobacter Pylori Infection:


fever, pruritus, nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.58 CASP3 CHUK CXCL8 IL1B JUN NFKB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.58 CASP3 CHUK CXCL8 IL1B JUN NFKB1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.58 JUN NFKB1

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.28 ADAM10 CASP3 CCL5 CHUK EGFR GAST
2 hematopoietic system MP:0005397 10.27 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
3 cellular MP:0005384 10.26 ADAM10 CASP3 CHUK EGFR IFNGR1 JUN
4 homeostasis/metabolism MP:0005376 10.25 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
5 cardiovascular system MP:0005385 10.24 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
6 endocrine/exocrine gland MP:0005379 10.22 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
7 digestive/alimentary MP:0005381 10.15 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
8 mortality/aging MP:0010768 10.13 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
9 craniofacial MP:0005382 10.11 ADAM10 CASP3 CHUK EGFR IL1B MET
10 integument MP:0010771 10.07 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
11 nervous system MP:0003631 9.9 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
12 neoplasm MP:0002006 9.8 CHUK EGFR GAST IFNGR1 IL1B MET
13 respiratory system MP:0005388 9.56 CASP3 CHUK EGFR JUN MET NFKB1
14 skeleton MP:0005390 9.32 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Titanium dioxide Approved Phase 4 13463-67-7
5
Famotidine Approved Phase 4 76824-35-6 3325
6
Coal tar Approved Phase 4 8007-45-2
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
11
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
12
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
13
Loperamide Approved Phase 4 53179-11-6 3955
14
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
15
Trimebutine Approved Phase 4 39133-31-8
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
19
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
20
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
23
Sulforaphane Investigational Phase 4 142825-10-3, 4478-93-7 5350
24
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
25
Meclocycline Investigational Phase 4 2013-58-3 5480760
26 Ubiquinone Phase 4
27 Antidotes Phase 4
28 Antioxidants Phase 4
29 Antiviral Agents Phase 4
30 N-monoacetylcystine Phase 4
31 diuretics Phase 4
32 Histamine Antagonists Phase 4
33
Histamine Phosphate Phase 4 51-74-1 65513
34 Histamine H2 Antagonists Phase 4
35 Acidophilus Phase 4
36 Hemostatics Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Respiratory System Agents Phase 4
39 Citrate Phase 4
40 Expectorants Phase 4
41 Neurotransmitter Agents Phase 4
42 Alkylating Agents Phase 4
43 Bifidobacterium Phase 4
44 Antitubercular Agents Phase 4
45 Antimalarials Phase 4
46 Bile Acids and Salts Phase 4
47 penicillins Phase 4
48 Fluoroquinolones Phase 4
49 Protective Agents Phase 4
50 Antidiarrheals Phase 4

Interventional clinical trials:

(show top 50) (show all 405)
# Name Status NCT ID Phase Drugs
1 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Unknown status NCT02934152 Phase 4 H pylori eradication
2 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
3 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
4 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
5 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
6 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
7 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
8 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
9 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
10 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
11 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
13 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
14 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
15 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
16 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
17 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
18 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
19 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
20 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
21 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
22 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
23 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
24 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
25 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
26 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
27 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
28 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
29 Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori Completed NCT01573975 Phase 4 5RA-5RCM;5RA-5RCT;10RCA
30 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
31 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
32 Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
33 Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials Completed NCT01967329 Phase 4 Standard Triple;Sequential;Quadruple
34 Phase IV Study Comparing the Duration of Sequential Therapy Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
35 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
36 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02490839 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
37 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
38 Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
39 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
40 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
41 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
42 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
43 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
44 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4 Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
45 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4 RAK therapy;RBAK therapy
46 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
47 The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates Completed NCT00825630 Phase 4 Lansoprazole (Lanton);Omeprezole (Losec);Pantoprazole(Controloc);Esomeprazole (Nexium)
48 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4 Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
49 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
50 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate

Search NIH Clinical Center for Helicobacter Pylori Infection

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

40
Testes, Colon, Liver, T Cells, B Cells, Heart, Kidney

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12536)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 61 6 56
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 61 56
15310903 2004
3
Transmission of Helicobacter pylori infection. 61 56
7672655 1995
4
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 61 56
7878011 1995
5
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 61 56
8185146 1994
6
Seroprevalence of helicobacter pylori infection in couples. 61 56
2037687 1991
7
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 56
22387998 2012
8
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 6
19488747 2009
9
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 56
18488030 2008
10
Helicobacter exploits integrin for type IV secretion and kinase activation. 56
17943123 2007
11
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 6
16690980 2006
12
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 56
15051885 2004
13
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 56
14555768 2003
14
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 56
14528007 2003
15
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 56
12598897 2003
16
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 56
12730721 2003
17
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 56
11902583 2002
18
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 56
11535550 2001
19
The complete genome sequence of the gastric pathogen Helicobacter pylori. 56
9252185 1997
20
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 56
8040281 1994
21
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 56
8163943 1994
22
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 56
8018146 1993
23
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 56
1587837 1992
24
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 56
6134060 1983
25
Helicobacter pylori prevalence in the Southwest of China: A protocol for systematic review. 42
32176059 2020
26
Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. 42
32352605 2020
27
Spotlight: Gastric Intestinal Metaplasia. 42
32035529 2020
28
Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy. 61
32524871 2020
29
Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection. 61
32353579 2020
30
Interleukin-8 heterozygous polymorphism (-251 T/A and +781 C/T) increases the risk of Helicobacter pylori-infection gastritis in children: a case control study. 61
32329328 2020
31
10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. 61
32028286 2020
32
Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome. 61
31714387 2020
33
Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. 61
32125555 2020
34
Periodontal disease and Helicobacter pylori infection in oral cavity: a meta-analysis of 2727 participants mainly based on Asian studies. 61
32474810 2020
35
Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience. 61
31599376 2020
36
Correlation of registered drug packs in Greece with Maastricht V/Florence and Hellenic Helicobacter pylori infection treatment consensuses: A poor or a proper match? 61
32346986 2020
37
Response to the Letter to the Editor entitled "Correlation of registered drug packs in Greece with Maastricht V/Florence and Hellenic Helicobacter pylori infection treatment Consensuses: A poor or a proper match?" 61
32306470 2020
38
Current Perspectives in Atrophic Gastritis. 61
32542467 2020
39
Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. 61
32548932 2020
40
What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? 61
31659615 2020
41
Data-Driven Development of an Institutional "Gross-Only" Policy for the Examination of Select Surgical Pathology Specimens. 61
32561904 2020
42
Effects of a formula with a probiotic Bifidobacterium lactis Supplement on the gut microbiota of low birth weight infants. 61
31197506 2020
43
Brunner's gland adenoma is a rare cause of upper gastrointestinal bleeding: A case report and literature review. 61
32327365 2020
44
The coeliac stomach: A review of the literature. 61
32295740 2020
45
Evaluation of RIDASCREEN® and RIDA®QUICK Helicobacter kits for Helicobacter pylori detection in stools. 61
32519216 2020
46
Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. 61
32141173 2020
47
Clinical course of duodenal mucosa-associated lymphoid tissue (MALT) lymphoma: Comparison with gastric MALT lymphoma. 61
32573049 2020
48
Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. 61
32545826 2020
49
Effect of early eradication therapy on systemic lupus erythematosus risk in patients with Helicobacter pylori infection: a nationwide population-based cohort study. 61
32380890 2020
50
Association Between Helicobacter pylori Infection and Otitis Media With Effusion Risk in Children: A Systematic Review and Meta-analysis. 61
32482139 2020

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IFNGR1 IFNGR1, -56C-TSNV protective,risk factor 17953

Expression for Helicobacter Pylori Infection

Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
2
Show member pathways
14.04 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
3
Show member pathways
13.98 PAK1 NFKBIA NFKB1 MET JUN IL1B
4
Show member pathways
13.83 PTPN11 NFKBIA NFKB1 MUC6 MET JUN
5
Show member pathways
13.83 NFKBIA NFKB1 MET JUN IL1B IFNGR1
6
Show member pathways
13.71 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
7
Show member pathways
13.57 PAK1 NFKB1 MET IL1B EGFR CXCL8
8
Show member pathways
13.54 PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
9
Show member pathways
13.47 PTPN11 NOD1 NFKB1 MET IL1B IFNGR1
10
Show member pathways
13.36 PAK1 NFKBIA NFKB1 JUN IL1B IFNGR1
11
Show member pathways
13.36 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
12
Show member pathways
13.23 PAK1 NFKBIA NFKB1 JUN EGFR CHUK
13
Show member pathways
13.21 NFKBIA NFKB1 JUN IL1B IFNGR1 EGFR
14
Show member pathways
13.17 PAK1 NFKB1 MET JUN EGFR CHUK
15
Show member pathways
13.15 PAK1 NFKBIA NFKB1 MET JUN CHUK
16
Show member pathways
13.07 PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
17
Show member pathways
13.04 PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
18 13.02 NFKBIA NFKB1 MET JUN IFNGR1 EGFR
19 13 PTPN11 NFKBIA NFKB1 IL1B IFNGR1 CHUK
20
Show member pathways
12.98 NFKBIA NFKB1 JUN IL1B IFNGR1 CXCL8
21 12.96 PAK1 NFKB1 MET JUN IL1B EGFR
22
Show member pathways
12.92 NOD1 NFKBIA NFKB1 JUN IL1B EGFR
23
Show member pathways
12.9 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
24
Show member pathways
12.89 PTPN11 NFKBIA NFKB1 JUN CHUK
25
Show member pathways
12.89 PTPN11 PAK1 NFKB1 MET EGFR CHUK
26
Show member pathways
12.88 PTPN11 NFKBIA NFKB1 MET EGFR CHUK
27
Show member pathways
12.86 NFKBIA NFKB1 MET IL1B EGFR CHUK
28
Show member pathways
12.86 NFKBIA NFKB1 JUN IL1B IFNGR1 EGFR
29
Show member pathways
12.82 NFKBIA NFKB1 JUN CHUK CASP3
30
Show member pathways
12.8 PAK1 NFKBIA NFKB1 JUN IFNGR1 CHUK
31
Show member pathways
12.79 PAK1 NFKB1 JUN EGFR CASP3
32
Show member pathways
12.79 PTPN11 PAK1 NFKB1 MET JUN EGFR
33
Show member pathways
12.79 PAK1 NFKBIA NFKB1 JUN IL1B CHUK
34
Show member pathways
12.78 PTPN11 PAK1 NFKBIA NFKB1 IL1B EGFR
35
Show member pathways
12.77 NFKBIA NFKB1 JUN IL1B IFNGR1 CHUK
36 12.74 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
37
Show member pathways
12.73 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
38
Show member pathways
12.72 PTPN11 NFKBIA NFKB1 JUN CHUK
39
Show member pathways
12.71 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
40
Show member pathways
12.66 PTPN11 PAK1 JUN IFNGR1 CASP3
41
Show member pathways
12.65 PAK1 NFKB1 JUN EGFR CASP3
42
Show member pathways
12.65 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
43
Show member pathways
12.63 PAK1 NFKBIA NFKB1 MUC6 IL1B CHUK
44
Show member pathways
12.6 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
45
Show member pathways
12.6 NFKBIA NFKB1 MET JUN IL1B EGFR
46
Show member pathways
12.59 NFKBIA NFKB1 JUN GAST EGFR CHUK
47
Show member pathways
12.58 PAK1 NFKBIA NFKB1 JUN CHUK
48
Show member pathways
12.57 PTPN11 NFKBIA NFKB1 JUN CHUK
49
Show member pathways
12.56 PAK1 MET JUN EGFR CASP3
50
Show member pathways
12.56 PTPN11 NFKBIA NFKB1 MET CHUK

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 S100A8 NFKB1 MUC6 MET IL1B GAST
2 I-kappaB/NF-kappaB complex GO:0033256 8.96 NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 NOD1 NFKB1 MET IL1B IFNGR1 GAST
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 NFKBIA NFKB1 MET JUN IL1B EGFR
3 positive regulation of transcription, DNA-templated GO:0045893 10.09 NFKBIA NFKB1 JUN IL1B EGFR CHUK
4 immune response GO:0006955 10.07 IL1B CXCL8 CXCL1 CHUK CCL5
5 intracellular signal transduction GO:0035556 10.06 NOD1 EGFR CXCL8 CXCL1 CASP3
6 apoptotic process GO:0006915 10.04 S100A8 PAK1 NOD1 NFKBIA NFKB1 IL1B
7 MAPK cascade GO:0000165 9.97 PAK1 MET IL1B EGFR CCL5
8 positive regulation of cell migration GO:0030335 9.97 PAK1 IL1B EGFR CCL5 ADAM10
9 cellular response to lipopolysaccharide GO:0071222 9.93 NFKB1 IL1B CXCL8 CXCL1
10 Fc-epsilon receptor signaling pathway GO:0038095 9.93 PAK1 NFKB1 JUN CHUK
11 chemotaxis GO:0006935 9.92 S100A8 CXCL8 CXCL1 CCL5
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 PTPN11 NOD1 JUN EGFR CCL5
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.88 PAK1 NFKB1 MUC6 CHUK
14 liver development GO:0001889 9.87 MET JUN EGFR
15 wound healing GO:0042060 9.86 S100A8 PAK1 EGFR CASP3
16 cellular response to interleukin-1 GO:0071347 9.85 NFKB1 CXCL8 CCL5
17 positive regulation of cell growth GO:0030307 9.85 S100A8 EGFR ADAM10
18 chemokine-mediated signaling pathway GO:0070098 9.85 CXCL8 CXCL1 CCL5
19 cellular response to organic cyclic compound GO:0071407 9.84 IL1B CCL5 CASP3
20 positive regulation of inflammatory response GO:0050729 9.84 S100A8 NFKBIA IL1B EGFR
21 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 NFKBIA NFKB1 CHUK
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 NOD1 IL1B EGFR
23 response to organic substance GO:0010033 9.83 PAK1 JUN CHUK CASP3
24 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 JUN EGFR CCL5
25 response to cytokine GO:0034097 9.82 NFKB1 JUN CCL5
26 positive regulation of interleukin-6 production GO:0032755 9.81 PTPN11 NOD1 IL1B
27 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 S100A8 NOD1 NFKB1 IL1B CHUK
28 cellular response to reactive oxygen species GO:0034614 9.79 JUN EGFR CHUK
29 cellular response to cadmium ion GO:0071276 9.78 JUN EGFR CHUK
30 cellular response to mechanical stimulus GO:0071260 9.78 PTPN11 NFKB1 IL1B EGFR
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 NFKBIA IL1B CCL5
32 response to tumor necrosis factor GO:0034612 9.77 CCL5 CASP3 ADAM10
33 cellular response to tumor necrosis factor GO:0071356 9.77 NFKBIA NFKB1 CXCL8 CHUK CCL5
34 interleukin-1-mediated signaling pathway GO:0070498 9.72 NOD1 NFKBIA NFKB1 IL1B CHUK
35 hepatocyte growth factor receptor signaling pathway GO:0048012 9.69 PAK1 MET
36 negative regulation by host of viral transcription GO:0043922 9.68 JUN CCL5
37 neutrophil activation GO:0042119 9.68 CXCL8 CCL5
38 neutrophil chemotaxis GO:0030593 9.65 S100A8 IL1B CXCL8 CXCL1 CCL5
39 astrocyte activation GO:0048143 9.63 IL1B IFNGR1 EGFR
40 response to lipopolysaccharide GO:0032496 9.63 S100A8 NFKBIA JUN IL1B CHUK CASP3
41 response to muscle stretch GO:0035994 9.61 NFKBIA NFKB1 JUN
42 cytokine-mediated signaling pathway GO:0019221 9.5 PTPN11 IL1B IFNGR1 CXCL8 CXCL1 CCL5
43 inflammatory response GO:0006954 9.23 S100A8 NOD1 NFKB1 IL1B CXCL8 CXCL1

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
2 identical protein binding GO:0042802 9.87 NOD1 NFKBIA NFKB1 MET JUN EGFR
3 cytokine activity GO:0005125 9.56 IL1B CXCL8 CXCL1 CCL5
4 protein-containing complex binding GO:0044877 9.35 NOD1 JUN EGFR CHUK CASP3
5 chemokine activity GO:0008009 8.8 CXCL8 CXCL1 CCL5

Sources for Helicobacter Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....